{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:54:49Z","timestamp":1791924889783,"version":"4.3.4"},"reference-count":18,"publisher":"American Society for Microbiology","issue":"9","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2017,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            We evaluated the activity of meropenem-vaborbactam against contemporary nonfastidious Gram-negative clinical isolates, including\n            <jats:named-content content-type=\"genus-species\">Enterobacteriaceae<\/jats:named-content>\n            isolates with resistance phenotypes and carbapenemase genotypes. Meropenem-vaborbactam (inhibitor at 8 \u03bcg\/ml) and comparators were susceptibility tested by reference broth microdilution methods against 14,304 Gram-negative clinical isolates collected worldwide during 2014. Carbapenemase-encoding genes were screened by PCR and sequencing. Meropenem-vaborbactam (MIC\n            <jats:sub>50\/90<\/jats:sub>\n            , \u22640.015\/0.06 \u03bcg\/ml) inhibited 99.1 and 99.3% of the 10,426\n            <jats:named-content content-type=\"genus-species\">Enterobacteriaceae<\/jats:named-content>\n            isolates tested at \u22641 and \u22642 \u03bcg\/ml, respectively. Meropenem inhibited 97.3 and 97.7% of these isolates at the same concentrations. Against\n            <jats:named-content content-type=\"genus-species\">Enterobacteriaceae<\/jats:named-content>\n            isolates displaying carbapenem-resistant\n            <jats:named-content content-type=\"genus-species\">Enterobacteriaceae<\/jats:named-content>\n            (CRE) (\n            <jats:italic>n<\/jats:italic>\n            = 265), multidrug-resistant (MDR) (\n            <jats:italic>n<\/jats:italic>\n            = 1,210), and extensively drug-resistant (XDR) (\n            <jats:italic>n<\/jats:italic>\n            = 161) phenotypes, meropenem-vaborbactam displayed MIC\n            <jats:sub>50\/90<\/jats:sub>\n            values of 0.5\/32, 0.03\/1, and 0.5\/32 \u03bcg\/ml, respectively, whereas meropenem activities were 16\/&gt;32, 0.06\/32, and 0.5\/32 \u03bcg\/ml, respectively. Among all geographic regions, the highest meropenem-vaborbactam activities were observed for CRE and MDR isolates from the United States (MIC\n            <jats:sub>50\/90<\/jats:sub>\n            , 0.03\/1 and 0.03\/0.12 \u03bcg\/ml, respectively). Meropenem-vaborbactam was very active against 135 KPC producers, and all isolates were inhibited by concentrations of \u22648 \u03bcg\/ml (133 isolates by concentrations of \u22642 \u03bcg\/ml). This combination had limited activity against isolates producing metallo-\u03b2-lactamases (including 25 NDM-1 and 16 VIM producers) and\/or oxacillinases (27 OXA-48\/OXA-163 producers) that were detected mainly in Asia-Pacific and some European countries. The activity of meropenem-vaborbactam was similar to that of meropenem alone against\n            <jats:named-content content-type=\"genus-species\">Pseudomonas aeruginosa<\/jats:named-content>\n            ,\n            <jats:named-content content-type=\"genus-species\">Acinetobacter<\/jats:named-content>\n            spp., and\n            <jats:named-content content-type=\"genus-species\">Stenotrophomonas maltophilia<\/jats:named-content>\n            . Meropenem-vaborbactam was active against contemporary\n            <jats:named-content content-type=\"genus-species\">Enterobacteriaceae<\/jats:named-content>\n            isolates collected worldwide, and this combination demonstrated enhanced activity compared to those of meropenem and most comparator agents against CRE isolates and KPC producers, the latter of which are often MDR.\n          <\/jats:p>","DOI":"10.1128\/aac.00567-17","type":"journal-article","created":{"date-parts":[[2017,6,27]],"date-time":"2017-06-27T00:30:31Z","timestamp":1498523431000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":155,"title":["Meropenem-Vaborbactam Tested against Contemporary Gram-Negative Isolates Collected Worldwide during 2014, Including Carbapenem-Resistant, KPC-Producing, Multidrug-Resistant, and Extensively Drug-Resistant Enterobacteriaceae"],"prefix":"10.1128","volume":"61","author":[{"given":"Mariana","family":"Castanheira","sequence":"first","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Huband","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo E.","family":"Mendes","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert K.","family":"Flamm","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.05041-11"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1086\/595011"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp255"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2015.03.001"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01019-15"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks063"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2012.0238"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5b00127"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00843-15"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt118"},{"key":"e_1_3_2_12_2","volume-title":"Abstr 54th Int Conf Antimicrob Agents Chemother","author":"Tarazi Z","year":"2014","unstructured":"Tarazi Z SabetM Rubio-AparicioD NolanT ParkinsonJ LomovskayaO DudleyMN GriffithDC. 2014. Efficacy of simulated human exposures of carbavance (meropenem-RPX7009) against carbapenem-resistant Enterobacteriaceae in an in vitro hollow fiber model, abstr F-959. Abstr 54th Int Conf Antimicrob Agents Chemother, 5 to 9 September 2014, Washington, DC."},{"key":"e_1_3_2_13_2","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard","author":"CLSI","year":"2012","unstructured":"CLSI. 2012. M07-A9. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 9th ed. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"9"},{"key":"e_1_3_2_14_2","volume-title":"Performance standards for antimicrobial susceptibility testing: 26th informational supplement","author":"CLSI","year":"2016","unstructured":"CLSI. 2016. M100-S26. Performance standards for antimicrobial susceptibility testing: 26th informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_15_2","unstructured":"EUCAST. 2016. Breakpoint tables for interpretation of MICs and zone diameters version 6.0 January 2016. http:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/v_6.0_Breakpoint_table.pdf."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2011.03570.x"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01802-13"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr081"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00826-13"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00567-17","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00567-17","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T20:54:29Z","timestamp":1645476869000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00567-17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":18,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["10.1128\/AAC.00567-17"],"URL":"https:\/\/doi.org\/10.1128\/aac.00567-17","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"2017-03-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-06-20","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-08-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00567-17"}}